Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia.
暂无分享,去创建一个
S Quaglini | G Barosi | A Centra | S Rupoli | S. Quaglini | G. Barosi | C. Finelli | D. Russo | A. Ambrosetti | L. Luciano | A Grossi | M. Ruggeri | E. Pogliani | A Ambrosetti | A Falcone | C Finelli | P Foa | R Guarnone | L Luciano | M C Petti | E Pogliani | D Russo | M Ruggeri | S. Rupoli | R. Guarnone | A. Falcone | M. Petti | A. Grossi | P. Foa | A. Centra | A. Centra | M. Ruggeri | L. Luciano
[1] J. Laszlo. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. , 1975, Seminars in hematology.
[2] A. Hart,et al. SPLENECTOMY IN HODGKIN'S DISEASE AND SECOND LEUKAEMIAS , 1987, The Lancet.
[3] L. Robison,et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. , 1996, The New England journal of medicine.
[4] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[5] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[6] J. Bosq,et al. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? , 1994, Blood.
[7] A. Hart,et al. Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Quaglini,et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. , 1993, Leukemia.
[9] R. Smart,et al. Prognostic Factors in Myelofibrosis , 1982, Pathology.
[10] David A. Schoenfeld,et al. Chi-squared goodness-of-fit tests for the proportional hazards regression model , 1980 .
[11] A. Varki,et al. The Syndrome of Idiopathic Myelofibrosis: A CLINICOPATHOLOGIC REVIEW WITH EMPHASIS ON THE PROGNOSTIC VARIABLES PREDICTING SURVIVAL , 1983, Medicine.
[12] L. Elveback,et al. Agnogenic myeloid metaplasia. Natural history and treatment. , 1967, Archives of internal medicine.
[13] Y. Najean,et al. Risks and benefits of splenectomy in myelofibrosis: an analysis of 39 cases. , 1994, Nouvelle revue francaise d'hematologie.
[14] H. Adami,et al. Risk of cancer following splenectomy , 1996, International journal of cancer.
[15] P. Voûte,et al. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors. , 2006, Medical and pediatric oncology.
[16] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[17] M. Cazzola,et al. Red cell aplasia in myelofibrosis with myeloid metaplasia. A distinct functional and clinical entity , 1983, Cancer.
[18] J. Fraumeni,et al. SPLENECTOMY AND SUBSEQUENT MORTALITY IN VETERANS OF THE 1939-45 WAR , 1977, The Lancet.
[19] M. Block,et al. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. , 1971, Medicine.
[20] J. Fermanian,et al. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Tefferi,et al. Agnogenic myeloid metaplasia. , 1995, Seminars in oncology.
[22] A. Hagenbeek,et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. , 1994, Journal of Clinical Oncology.
[23] S. Pileri,et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients , 1990, British journal of haematology.
[24] P. Morel,et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.
[25] J. Pitcock,et al. A clinical and pathological study of seventy cases of myelofibrosis. , 1962, Annals of internal medicine.
[26] A. Tichelli,et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. , 1993, The New England journal of medicine.
[27] S. Emery,et al. Natural History and Treatment , 1997 .
[28] B. Bouroncle,et al. MYELOFIBROSIS CLINICAL, HEMATOLOGIC AND PATHOLOGIC STUDY OF 110 PATIENTS , 1962, The American journal of the medical sciences.
[29] M. Laval-Jeantet,et al. Prognosis of myeloid metaplasia with myelofibrosis. , 1976, Biomedicine / [publiee pour l'A.A.I.C.I.G.].
[30] D. Arthur,et al. Transformation of chronic myelogenous leukemia: clinical, morphologic, and cytogenetic features. , 1984, American journal of clinical pathology.
[31] S. Lewis,et al. Erythroid Hypoplasia in Myelofibrosis: a Feature Associated with Blastic Transformation , 1977, British journal of haematology.
[32] M. Hudson,et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] S. Zimmerman,et al. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] N. Day,et al. Leukemia following Hodgkin's disease. , 1990, The New England journal of medicine.
[35] W. Moloney,et al. Reduction of leukemia incidence following splenectomy in the rat. , 1973, Cancer research.
[36] A. Hagenbeek,et al. Subsequent development of acute non‐lymphocytic leukemia in patients treated for Hodgkin's disease , 1988, International journal of cancer.
[37] P. Gobbi,et al. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] S. Kvaløy,et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] A. Tefferi. Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.
[40] L. Fisher,et al. Prognostic models and the propensity score. , 1995, International journal of epidemiology.
[41] M. Block. Agnogenic myeloid metaplasia. , 1974, Revista brasileira de pesquisas medicas e biologicas.
[42] D.,et al. Regression Models and Life-Tables , 2022 .
[43] K. Nason-Burchenal,et al. Involvement of the spleen in preleukemic development of a murine retrovirus-induced promonocytic leukemia. , 1992, Cancer research.